Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?

Physicians always aim to improve their patients’ health. CME should be designed not only to provide knowledge transfer, but also to influence clinical decision-making and to close performance gaps. In aretrospective study we analysed prescription rates for APT in 254,932 CAD patients (male: 64.4%),...

Full description

Bibliographic Details
Main Authors: Bernd Hagen, Reinhard Griebenow
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Journal of European CME
Subjects:
Online Access:http://dx.doi.org/10.1080/21614083.2020.1836866
id doaj-4899b4ee084e4c96a84ab1fd7eb4de55
record_format Article
spelling doaj-4899b4ee084e4c96a84ab1fd7eb4de552020-12-17T14:55:57ZengTaylor & Francis GroupJournal of European CME2161-40832020-01-019110.1080/21614083.2020.18368661836866Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?Bernd Hagen0Reinhard Griebenow1Central Institute for Statutory Health Care in GermanyUniversity of ColognePhysicians always aim to improve their patients’ health. CME should be designed not only to provide knowledge transfer, but also to influence clinical decision-making and to close performance gaps. In aretrospective study we analysed prescription rates for APT in 254,932 CAD patients (male: 64.4%), treated in atotal of 3,405 practices in 2019 in aDMP in the region of North Rhine, Germany. Analyses were run for the whole study population stratified by sex as well as for subgroups of patients suffering from myocardial infarction/acute coronary syndrome, or who have been treated with percutaneous coronary intervention or bypass surgery. Patients mean age was 72.7 ± 11.2 years (mean ± 1SD), mean duration of DMP participation was 7.2 ± 4.7 years, and mean cumulative number of DMP visits was 27 ± 17. APT prescription rates were 85.0% in male and 78.8% in female CAD patients. In subgroups of male CAD patients APT prescription rates were between 89.7% and 92.8%, in the same subgroups of female CAD patients the corresponding rates were between 87.8% and 92.0%. Rates for amissing APT prescription per practice were between .0044% and .0062% for male and female CAD patients, respectively. Rates for amissing APT prescription per practice and DMP visit were .0002% for both sexes. These results suggest that a DMP can achieve high attainment rates for APT in CAD. To further improve attainment rates, consideration of absolute numbers of eligible patients per practice or physician is probably more appropriate than expression of performance as percentage values. This is especially true if attainment rates show substantial variations between subgroups, if subgroups show substantial variation in size, if attainment rates are already in the magnitude of 80% or higher, and if there are disparities in the evidence base underlying treatment recommendations related to subgroups.http://dx.doi.org/10.1080/21614083.2020.1836866coronary artery diseaseantiplatelet therapydisease management programmebenchmarkfeedback reportcommunity health
collection DOAJ
language English
format Article
sources DOAJ
author Bernd Hagen
Reinhard Griebenow
spellingShingle Bernd Hagen
Reinhard Griebenow
Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?
Journal of European CME
coronary artery disease
antiplatelet therapy
disease management programme
benchmark
feedback report
community health
author_facet Bernd Hagen
Reinhard Griebenow
author_sort Bernd Hagen
title Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?
title_short Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?
title_full Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?
title_fullStr Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?
title_full_unstemmed Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?
title_sort prescription rates for antiplatelet therapy (apt) in coronary artery disease (cad) – what benchmark are we aiming at in continuing medical education (cme)?
publisher Taylor & Francis Group
series Journal of European CME
issn 2161-4083
publishDate 2020-01-01
description Physicians always aim to improve their patients’ health. CME should be designed not only to provide knowledge transfer, but also to influence clinical decision-making and to close performance gaps. In aretrospective study we analysed prescription rates for APT in 254,932 CAD patients (male: 64.4%), treated in atotal of 3,405 practices in 2019 in aDMP in the region of North Rhine, Germany. Analyses were run for the whole study population stratified by sex as well as for subgroups of patients suffering from myocardial infarction/acute coronary syndrome, or who have been treated with percutaneous coronary intervention or bypass surgery. Patients mean age was 72.7 ± 11.2 years (mean ± 1SD), mean duration of DMP participation was 7.2 ± 4.7 years, and mean cumulative number of DMP visits was 27 ± 17. APT prescription rates were 85.0% in male and 78.8% in female CAD patients. In subgroups of male CAD patients APT prescription rates were between 89.7% and 92.8%, in the same subgroups of female CAD patients the corresponding rates were between 87.8% and 92.0%. Rates for amissing APT prescription per practice were between .0044% and .0062% for male and female CAD patients, respectively. Rates for amissing APT prescription per practice and DMP visit were .0002% for both sexes. These results suggest that a DMP can achieve high attainment rates for APT in CAD. To further improve attainment rates, consideration of absolute numbers of eligible patients per practice or physician is probably more appropriate than expression of performance as percentage values. This is especially true if attainment rates show substantial variations between subgroups, if subgroups show substantial variation in size, if attainment rates are already in the magnitude of 80% or higher, and if there are disparities in the evidence base underlying treatment recommendations related to subgroups.
topic coronary artery disease
antiplatelet therapy
disease management programme
benchmark
feedback report
community health
url http://dx.doi.org/10.1080/21614083.2020.1836866
work_keys_str_mv AT berndhagen prescriptionratesforantiplatelettherapyaptincoronaryarterydiseasecadwhatbenchmarkareweaimingatincontinuingmedicaleducationcme
AT reinhardgriebenow prescriptionratesforantiplatelettherapyaptincoronaryarterydiseasecadwhatbenchmarkareweaimingatincontinuingmedicaleducationcme
_version_ 1724379214918975488